We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Plasticell Completes £1.32 Million Financing to Advance Therapeutic Projects
News

Plasticell Completes £1.32 Million Financing to Advance Therapeutic Projects

Plasticell Completes £1.32 Million Financing to Advance Therapeutic Projects
News

Plasticell Completes £1.32 Million Financing to Advance Therapeutic Projects

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Plasticell Completes £1.32 Million Financing to Advance Therapeutic Projects "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The investment will provide capital to progress the company’s therapeutic programmes, including the expansion of hematopoietic stem cells and in vitro manufacturing of blood products such as platelets, red blood cells and cancer immunotherapies.

Plasticell specialises in using massively parallel screening technologies to optimise high value cell therapies derived from stem cells. Its award-winning platform technology, CombiCult®, can be applied to any cell culture process, including biopharmaceutical production, as well as cell and gene therapy manufacturing.

Plasticell’s lead therapeutic programme is in the expansion of hematopoietic stem cells derived from bone marrow and cord blood. Last year the company announced it received a grant of approximately £1.3 million from Innovate UK to develop GMP manufacturing for this therapy in collaboration with the University of Oxford and the Cell and Gene Therapy Catapult over three-years.

Dr Yen Choo, Executive Chairman of Plasticell, commented: “Together with non-dilutive financing from multiple government grants, this latest equity fundraising provides the capital required to progress our lead therapeutic programme towards the clinic.”

Source:

Original article from Plasticell. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines. 

Advertisement